Literature DB >> 27388576

Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression.

Rana Ahmed Youness1, Mai Atef Rahmoon1, Reem Amr Assal2, Asmaa Ibrahim Gomaa3, Mohamed Tarif Hamza4, Imam Waked3, Hend Mohamed El Tayebi2, Ahmed Ihab Abdelaziz5.   

Abstract

In this study, an impaired natural killer (NK) cell cytolytic activity in 135 hepatocellular carcinoma (HCC) patients parallel to a reduced expression level of insulin-like growth factor (IGF)-1 in NK cells of HCC patients has been revealed. Ectopic expression of miR-486-5p, a direct upstream regulator of IGF-1, restored the endogenous level of IGF-1 in NK cells of HCC patients, thus augmenting its cytolytic activity against Huh7 cells in an opposite manner to the IGF-1 siRNAs. Unorthodoxly, over-expression of miR-486-5p in target hepatocytes resulted in the repression of IGF-1, suppression of Huh7 cells proliferation and viability in a similar pattern to the IGF-1 siRNAs. Therefore, this study highlights a potential role of IGF-1 in modulating cytolytic potential of NK cells of HCC patients. miR-486-5p acts in a cell-specific manner, differentially modulating IGF-1 expression in NK cells and their target hepatocytes with a contemporary inhibitory impact on HCC progression.

Entities:  

Keywords:  Insulin-like growth factor-1; NKG2A; NKG2D; hepatocellular carcinoma; immunotherapy; miR-486-5p; natural killer cells; perforins

Mesh:

Substances:

Year:  2016        PMID: 27388576     DOI: 10.1080/08977194.2016.1200571

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  8 in total

1.  MALAT-1/p53/miR-155/miR-146a ceRNA circuit tuned by methoxylated quercitin glycoside alters immunogenic and oncogenic profiles of breast cancer.

Authors:  Mustafa Abdel-Latif; Ahmed Riad; Raghda A Soliman; Aisha M Elkhouly; Heba Nafae; Mohamed Z Gad; Amira Abdel Motaal; Rana A Youness
Journal:  Mol Cell Biochem       Date:  2022-02-07       Impact factor: 3.396

Review 2.  Decoding Insulin-Like Growth Factor Signaling Pathway From a Non-coding RNAs Perspective: A Step Towards Precision Oncology in Breast Cancer.

Authors:  Yousra Ahmed ZeinElAbdeen; Amna AbdAlSeed; Rana A Youness
Journal:  J Mammary Gland Biol Neoplasia       Date:  2022-02-10       Impact factor: 2.673

3.  Ginsenoside F1 Promotes Cytotoxic Activity of NK Cells via Insulin-Like Growth Factor-1-Dependent Mechanism.

Authors:  Hyung-Joon Kwon; Heejae Lee; Go-Eun Choi; Soon Jae Kwon; Ah Young Song; So Jeong Kim; Woo Seon Choi; Sang-Hyun Hwang; Sun Chang Kim; Hun Sik Kim
Journal:  Front Immunol       Date:  2018-11-28       Impact factor: 7.561

Review 4.  The role of natural killer cells in hepatocellular carcinoma development and treatment: A narrative review.

Authors:  Sarun Juengpanich; Liang Shi; Yasaman Iranmanesh; Jiang Chen; Zhenzhe Cheng; Aaron Kah-Jin Khoo; Long Pan; Yifan Wang; Xiujun Cai
Journal:  Transl Oncol       Date:  2019-06-06       Impact factor: 4.243

Review 5.  Targeting hydrogen sulphide signaling in breast cancer.

Authors:  Rana Ahmed Youness; Ahmed Zakaria Gad; Khaled Sanber; Yong Jin Ahn; Gi-Ja Lee; Emad Khallaf; Hafez Mohamed Hafez; Amira Abdel Motaal; Nabil Ahmed; Mohamed Zakaria Gad
Journal:  J Adv Res       Date:  2020-07-16       Impact factor: 10.479

6.  What is beyond LncRNAs in breast cancer: A special focus on colon cancer-associated Transcript-1 (CCAT-1).

Authors:  Noha A Selem; Rana A Youness; Mohamed Z Gad
Journal:  Noncoding RNA Res       Date:  2021-12-01

Review 7.  Nonviral genome engineering of natural killer cells.

Authors:  Gabrielle M Robbins; Minjing Wang; Emily J Pomeroy; Branden S Moriarity
Journal:  Stem Cell Res Ther       Date:  2021-06-16       Impact factor: 6.832

8.  An Anti-inflammatory microRNA Signature Distinguishes Group 3 Innate Lymphoid Cells From Natural Killer Cells in Human Decidua.

Authors:  Andrea Pelosi; Claudia Alicata; Nicola Tumino; Tiziano Ingegnere; Fabrizio Loiacono; Maria Cristina Mingari; Lorenzo Moretta; Paola Vacca
Journal:  Front Immunol       Date:  2020-02-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.